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A surprising common pathological processes is found between Alzheimer’s disease (AD) and type 
2 diabetes mellitus (T2DM)
[1]. AD and T2DM share some common pathological processes: Amyloid 
β (Aβ), τ hyperphosphoralation, insulin abnormality. Disturbance in insulin signalling is not only 
involved in blood glucose level but also in numerous degenerative processes. Glucagon-like peptide 
1 (GLP-1) has attracted substantial attention for its advantage in treating T2DM. GLP-1 can reduce 
Aβ levels in brain. All these encourage us in a medical hypothesis: that is, that GLP-1 is a promising 
agent in the therapy of AD.
Commonalities Between T2DM and AD
Both AD and T2DM are the most common degenerative diseases and their prevalence increase with 
age. Numerous epidemiological studies have linked T2DM with an increased risk of AD
[2]. An inves-
tigation of cohort of 1,301 in Stockholm, Sweden showed that T2DM increased the risk of dementia
[3].
In another survey of 683 subjects cohort of persons aged 65 years and older with hyperinsulinemia in 
northern Manhattan is shown to be associated with a higher risk of AD and decline in memory
[4]. In a 
prospective population-based cohort study among 6,370 elderly subjects, Ott
[5] revealed that diabetes 
may have contributed to the clinical syndrome in a substantial proportion of all dementia patients. 
Peila
[6] evaluated the association of diabetes alone or combined with the apolipoprotein E (ApoE) gene 
with incident dementia in a population-based cohort of 2,574 Japanese-American men. The result 
displayed that T2DM is a risk factor for AD. The association between diabetes and AD is particularly 
strong among carriers of the APOE epsilon4 allele.
Commonalities between T2DM and AD in epidemiology: such as degenerative change, aging diseases, 
fat and higher cholesterol, and cardiac risk factors, encourage us to look for the linkage of both. Research 
has shown an extensive expression of insulin and its receptor throughout the mammalian brain
[7,8] . A fact 
of commonalities between neurons and β-cells launch into a reasonable explanation as to the common 
risk and prevention factors between T2DM and AD. Research has shown some common risk factors 
between T2DM and AD: higher cholesterol
[9], dis-metabolism, degeneration
[9], myloid β (Aβ) deposi-
tion
[9], Glycogen synthesis kinase 3(GSK3), and τ protein phosphorylation
[10], cardiovascular disease, 
oxidative stress
[2], inﬂ  ammation
[2], ApoE4
[11], apoptosis etc. A new ﬁ  nding shows that treatment with 
GLP-1 beneﬁ  cially affects a number of the therapeutic targets associated with AD. This ﬁ  nding opens 
a new research area. The commonalities between T2DM and AD may contribute to the explanation of 
GLP-1 as a promising peptide to treat T2DM and AD.
AD is characterized by intracellular neuroﬁ  brillary tangles (NFTs), containing an abnormal hyper-
phosphorylated form of τ protein, and extracellular senile plaques (SPs), mainly composed of ﬁ  brillar 
Aβ. Both of those hallmarks are involved in T2DM
[1]. Both age-related degenerative diseases, AD and 
T2DM, are associated with the accumulation of amyloid ﬁ  brils
[12]. Another commonality, cell loss and 
degenerative change, is also involved in both diseases. AD is the most common neurodegenerative 
disease with an extensive neuron loss. T2DM is also a degenerative disease that results from the selective 
destruction of pancreatic β cells
[13].84
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Aβ deposits are commonly observed in 
pancreatic islets of diabetic patients. These 
deposits consist of islet amyloid polypeptide 
(IAPP)
[14].Considering the pathogenetic similari-
ties and the 90% structural similarity between Aβ 
precursor protein and IAPP
[15], it should not be 
surprising that AD seems to be predisposed to 
insulin resistance, insulin hypersecretion, and 
T2DM
[2]. Similarly, individuals suffering from 
T2DM will suffer from dementia more readily
[5,16]. 
The research has shown that a higher serum 
insulin level in prediabetes and early T2DM has 
been associated with impaired cognitive func-
tion
[17]. Mechanistically this might be that eleva-
tion of Aβ levels is associated with elevated serum 
insulin content
[18]. In other words, the evidence 
of the existence of links between AD and T2DM 
is that AD is associated with peripheral and central 
insulin abnormalities, and that cognitive capaci-
ties are often impaired in patients with T2DM
[14]. 
The complex relationship between insulin, cho-
lesterol, and AD was well described by Nelson
[19]. 
Insulin regulates cholesterol biosynthesis by 
stimulating activity of 3-hydroxy-3-methylglutaryl-
CoA reductase, a rate-limiting enzyme in choles-
terol biosynthesis. Cholesterol is involved in AD 
by multifactor: ApoE4, Aβ deposition, amyloid 
precursor protein (APP) metabolism etc. Hyper-
cholesterolemia is an obvious risk factor of 
T2DM
[20]. It was shown that transgenic mice 
models overexpressing IAPP develop diabetes and 
generally subsequent to amyloid deposits
[21,22]. 
Conversely, targeted disruption of IAPP leads to 
enhanced insulin secretion and improved glucose 
tolerance
[23].
Freude
[24] showed a correlation between τ 
phosphorylation and peripheral insulin level with 
a signiﬁ  cant increase in τ phosphorylation at Ser
202 
in the brain within 10 min after 1-mU insulin 
injection and an even further increase after injec-
tion of 4 units insulin. Further, Freude demon-
strated that insulin receptor signaling and 
τ phosphorylation were completely abolished in 
the brains of the mice lacking the brain insulin 
receptor under hyperinsulinemic conditions, indi-
cating that the cerebral insulin receptors are a direct 
target of peripheral administered insulin. Further 
evidence of τ phosphorylation involvement in AD 
and T2DM is that GSK-3, a serine/threonine kinase 
that phosphorylates glycogen synthase in the rate-
limiting step of glycogen biosynthesis, was 
implicated in the formation of NFTs
[25,26]. 
GSK-3 inhibitor is an attractive target identiﬁ  ed 
to be useful in the treatment of diseases such as 
T2DM and AD
[27].
Common biological characteristics between the 
pancreas and the brain also include common 
enzymes: glutamic acid decarboxylase, tyrosine 
hydroxylase, and dopa decarboxylase, thyrotro-
phin-releasing hormone, and P75. Neuron growth 
factor receptors are also shared attributes of both 
neuronal tissues and β-cells. β-cells resemble 
neurons in that they are electrically excitable and 
respond to hormonal stimuli and glucose by depo-
larization and exocytosis, in a process that resem-
bles neurotransmitter release from synaptic 
vesicles. All those commonalities approve a rea-
sonable assumption that common signaling 
mechanisms occur in response to similar physio-
logical responses, such as proliferation and 
differentiation
[28]. Furthermore the impact of type 
1 diabetes on brain development and function has 
been reviewed by Northam
[29]. Either hypoinsu-
linemia or hyperinsulinemia are involved in the 
damage of brain development.
There is growing evidence that insulin is 
involved in cognitive decline and AD
[30]. The 
evidence includes the insulin resistance of brain 
owing to alterations of insulin receptor signaling 
in the brain, and regulation of insulin to the 
metabolism of Aβ and τ protein. It is further 
evidence that there is widely distribution of insu-
lin and insulin receptor (IR) in the brain, especially 
in the hypothalamus and the hippocampus
[31]. The 
hippocampus- and cerebral cortex-distributed 
insulin/IR has also been shown to be involved in 
brain cognitive functions. In contrast, deterioration 
of insulin receptor signaling is involved in aging-
related brain degeneration such as the AD and 
cognitive impairment in T2DM patients
[31]. 
Moroo
[32] showed a decrease of expression of IR 
in the brain in AD and PD patients. Frolich
[33] 
compared the expression of insulin and its IR in 
neocortical brain areas of AD patients with normal 
controls by immunohistochemical staining. The 
result showed that insulin and its receptor densities 
decrease with aging. Brain IR densities in AD were 
decreased compared to middle-aged controls. The 
effect of insulin in AD patients includes: 1) AD 
may be associated with an impairment of glucose 
regulation. 2) AD may worsen insulin abnormali-
ties. 3) AD patients may have a decreased cere-
brospinal ﬂ  uid insulin levels and/or a decreased 
cerebrospinal fluid-to-plasma insulin ratios. 85
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4) Acute glucose administration can facilitate 
memory of AD patients and healthy older adults; 
however, it is abolished by suppressing endoge-
nous insulin secretion. 5) Acute insulin administra-
tion facilitates memory of AD patients. 6) Apo E 
does not only involve in AD but also moderates 
insulin activity and affects on memory of patients 
with AD. Patients without an APOE ε4 allele have 
lower insulin sensitivity and occur insulin-induced 
memory facilitation at higher insulin doses. 
Reversely, Patients with at least one APOE q4 
allele show insulin-induced memory facilitation 
at lower insulin doses and reduced insulin degrad-
ing enzyme levels. Hence, disturbances in cerebral 
insulin signalling pathways may be involved in 
AD and brain aging
[34].
The relation between insulin and the metabo-
lism of Aβ and τ is also receiving increasing atten-
tion. Insulin appears to stimulate Aβ secretion and 
inhibits the extracellular degradation of Aβ due to 
competition from insulin-degrading enzyme 
(IDE)
[35].
Hyperglycaemia may be involved in the brain 
damage. Hyperglycaemic rodents, for example, 
express cognitive impairments and functional and 
structural alterations in the brain
[36]. Schubert
[37] 
hypothesized that neuronal insulin resistance con-
tributes to defects in neuronal function and exhib-
ited the evidence in insulin receptor knockout 
(NIRKO) mice. A complete loss of insulin-
mediated activation of phosphatidylinositol 
3-kinase and inhibition of neuronal apoptosis was 
shown in NIRKO mice. As a result, phosphoryla-
tion of GSK3 was markedly reduced and phos-
phorylation of τ protein increased. The hypothesis 
should be further completed because Schubert has 
not exhibited the alteration of neuronal prolifera-
tion survival, memory, or basal brain glucose 
metabolism in NIRKO mice. Involvement of other 
factor will be needed to develop AD based on 
changes in GSK3 activity and hyperphosphoryla-
tion of τ protein induced by lack of insulin signal-
ing in the brain.
A complex relationship between diabetes and 
AD is shown in the Figure 1. Ninety percent struc-
tural similarity was founded in Aβ which is a 
hallmark pathology in AD and IAPP which is 
involved in T2DM. Insulin abnormality is attrib-
uted to AD by promoting Aβ deposition, and 
τ protein hyperphosphorylation. GSK3 is a key 
kinase to promote τ protein hyperphosphorylation 
and glycogen biosynthesis.
A New Strategy Consideration 
to Treat AD
A cure of AD is still far off, and clinicians face the 
burden of caring for patients at all stages of demen-
tia for the foreseeable future
[38]. Heretofore, therapy 
strategies of AD, including the cholinesterase 
inhibitors, are only limited in heteropathy: improving 
cognitive impairment, decreasing complication, 
preventing abnormity behaviors, and avoiding 
psychopathic affair. Effective strategies aimed at the 
hallmarks of AD, and developing therapies that 
target Aβ production, aggregation, clearance or 
toxicity are likely to appear in the near future
[39,40].
The therapy strategy aimed at other hallmarks of AD, 
neuroﬁ  brillary tangles, is also being developed
[41].
Even with treatment, patients with T2DM may 
face some troubles: spikes in blood glucose after 
meals, weight gain, a loss of effectiveness of their 
treatments over time etc. GLP-1 draws on a better 
understanding of how the body responds to 
meals—some already available and may offer use-
ful adjuncts to existing therapies
[42].
Emerging literature, in which it is shown that 
hallmarks of AD can link to T2DM, and GLP-1 
can reduce Aβ-peptide levels in the brain, encour-
age an adventurous thinking: is GLP-1 a new hope 
for the therapy of AD?
Synthesis, Secretion and Function 
of GLP-1
GLP-1 originates from expression of the glucagon 
gene in the L cells of the distal intestinal mucosa 
and contains 30 amino acids with 50% sequence 
homology to glucagons
[43–45]. GLP-1 was found as 
an insulinogenic factor 20 years ago. In all candi-
date incretins, insulinogenic factors of the gastro-
intestinal mucosa, GLP-1 was regarded as the most 
physiological signiﬁ  cation, possessing obvious 
characters of gastrone and insulinotropic sub-
stances
[46]. Its effects on glucose-dependent insulin 
secretion and insulin gene expression have been 
proven
[47,48]. The mechanism of GLP-1 to regulate 
blood glucose include 1) the stimulation of insulin 
secretion and of its gene expression, 2) the inhibi-
tion of glucagon secretion, 3) the inhibition of food 
intake, 4) the proliferation and differentiation of 
β cells, and 5) the protection of β cells from apop-
tosis
[49]. 6) formation of pancreatic islet mass.
New discovery that GLP-1 and Exendin-4 
(Ex-4), a naturally occurring stable analogue of 
GLP-1 that binds at the GLP-1 receptor (GLP-1R), 86
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possess neurotrophic properties and can protect 
neurons against glutamate-induced apoptosis and 
reduce level of Aβ in brain, prompt a new consid-
eration: GLP-1 and its mimics are promising agents 
in therapy of AD. GLP-1 is also regarded as a 
promoting agent not only for T2DM but also for 
AD due to its extensive expression of GLP-1R in 
the brain
[50–52].
In the human genome, the proglucagon gene is 
located on chromosome 17 spanning approxi-
mately 10 kb. The transcriptional unit of proglu-
cagon contain six exons and ﬁ  ve introns
[53]. The 
posttranslational processing of preproglucagon 
differs in different tissue. They are, in the pancreas, 
GLP-1 (1–36 amide) and GLP-1 (1–37), while, in the 
ileum and hypothalamus, are GLP-1 (7–36)-amide 
and GLP-1 (7–37)
[54]. In the pancreatic islet 
alpha-cells proglucagon is processed by proprotein 
convertase 2 to release mainly glucagon. In the 
intestinal L cells it is by proprotein convertase to 
produce mainly GLP-1, GLP2
[55]. Amidation of 
GLP-1 has been regard as a chemical process to 
enhance its survival in the bloodstream. In the 
pancreas, the carboxyl-terminal amidation of 
GLP-1 is processed by the sequential enzymatic 
action by peptidylglycine α-monooxygenase and 
peptidy-lamidoglycolate lyase
[56]. The signiﬁ  cance 
of the amidated forms of GLP-1 in nonpancreatic 
targets is not clear. GLP-1 has a very short half-life 
(1–2 min) and is rapidly degraded in vivo by dipep-
tidyl peptidase-IV (DPP-IV), which cleaves 
GLP-1 at the penultimate N-terminal site of 
Ala
8[57-59]. Fortunately, all GLP-1 analogues have 
been developed to possess a longer half-life. 
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Figure 1. Common pathological processes in AD and T2DM. Ninety percent homologous structure was shown between Aβ which is a hallmark 
pathology in AD and IAPP which is involved in T2DM. Insulin abnormality is attributed to AD by promoting Aβ deposite, and τ protein 
hyperphosphorylation. GSK3 is a key kinase to promoteτ protein hyperphosphorylation and glycogen biosynthesis.
Abbreviations: AD: Alzheimer’s disease; T2DM: Type 2 diabetes mellitus; IAPP: islet amyloid polypeptide; Aβ: Amyloid β; GSK3: glycogen 
synthase kinase.87
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In vivo, several metabolites of GLP-1 are formed 
by enzyme digestion. They are GLP-1 (9–36), 
GLP-1 (7–35), and GLP-1 (7–34). GLP-1 (9–36) 
amide, a main metabolite of GLP-1, is present in 
vivo in concentrations that are up to 10-fold greater 
than the level of GLP-1(7–36) amide
[60]. Isoforms 
of GLP-1 show different bioactivity; the 
effect of GLP-1 (7–36) amide is 100 times more 
potent than GLP-1 (1–37) and GLP-1 (1–36) 
amide in stimulating [
14C]-aminopyrine accumula-
tion
[61]; GLP-1 [7–36 amide] and GLP-1 [7–37] 
possess an efﬁ  ciency
[62].GLP-1 (9–36) amide has 
been shown to have no effects on β cells and it is 
in some studies shown as an antagonist of the 
adenylyl cyclase activity
[63]. The research also 
showed that GLP-1 (7–35) and GLP-1 (7–34) are 
an agonists. GLP-1 (7–36) and GLP-1 (7–37) are 
two of the main naturally occurring GLP products 
in vivo and the similar insulinotropic potency is 
proven. The structural analysis of GLP-1 shows 
that the ﬁ  rst seven amino acid residues form a 
random coil structure followed by a ﬁ  rst helical 
region (7–14), a linker region (15–17) and another 
helical region (18–29). Plasma levels of GLP-1 
rise rapidly following nutrient ingestion. Major 
regulating factors of GLP-1 secretion are pancre-
atic hormones (insulin and glucagon)
[64,65], 
nutrients (glucose and fatty acids), gastrointestinal 
hormones (gastric inhibitory polypeptide), gastrin-
releasing polypeptide, gastric emptying
[66,67], 
satiety
[68], body weight
[69], the vagal nerve-
dependent release of acetylcholine etc
[70,71]. 
Glucose-dependent Insulinotropic Peptide was also 
shown as an attractive stimulator of GLP-1 release 
in vitro
[72]. GLP-1 secreted from intestinal L cells 
is inactivated by DPP-IV in intestinal capillaries. 
DPP-IV deactivates GLP-1 by cleavage of the 
N-terminal dipeptide. Thus only 25% of GLP-1 
secreted enters the portal circulation in its intact 
form. In the liver 40% of the remaining active 
GLP-1 is further inactivated. As a result, only 
10%–15% of GLP-1 reaches the systemic 
circulation and the pancreas. GLP-1 imposes on 
the brain by activating sensory efferent neurons 
from the nodose ganglion, the hepatoportal 
region
[73,74] or the liver
[75], and stimulating the 
neural pathway
[76].
GLP-1R, a member of the seven-membrane-
spanning G-protein-coupled family of receptor, is 
localized on chromosome 6 with 12 introns and 
13 exons
[49,77]. GLP-1R have been identiﬁ  ed in 
brain, lung, pancreatic islets, stomach, hypothalamus, 
heart, intestine, and kidney
[78,79]. GLP-1R consists 
of 463 amino acids (with a molecular weight of 
65000 D) with eight hydrophobic domains. The 
hydrophobic segment located N-terminal is 
probably a signal area, whereas the others are 
membrane-spannin hydrophobic motifs
[80]. GLP-1 
receptor efﬁ  ciently stimulate insulin secretion by 
coupling with adenyl cyclase
[81].
GLP-1, an Attractive Agent to Treat 
T2DM and AD
Numerous researches has shown that GLP-1 is an 
attractive agent in therapy of T2DM
[42,59,82,83]. Its 
pharmacological actions in glucose metabolism, 
including stimulation of insulin release, suppres-
sion of glucagon release, and inhibition of gastric 
emptying, ensure the rationale for its assessment 
as a therapeutic agent for T2DM
[84]. The research 
recently focusing on intervening AD showed that 
GLP-1 is also a strong intervenor of AD
[28,51,52].
GLP-1 regulates insulin secretion and insulin 
gene expression via its action on the pancreas 
following binding at the G-protein coupled 
GLP-1R. The GLP-1R signaling has been demon-
strated to inhibit glucagon secretion
[85]. It has been 
demonstrated that the commonality of expression 
of GLP-1R in both the rat and human brain 
exists
[86]. Within the central nervous system (CNS), 
GLP-1 and several analogs that bind it to the 
GLP-1R possess neurotrophic properties and offer 
protection against glutamate-induced apoptosis and 
oxidative injury in cultured neuronal cells
[87]. 
Moreover, GLP-1 can modify the processing of 
Aβ precursor protein in cell cultures and reduce 
Aβ levels in the brain in vivo
[88].
The stimulus for neuronal GLP-1-transmission 
within the CNS is unclear. One possibility is that 
GLP-1-containing neurons or receptors are impli-
cated in other neuropeptide-containing CNS 
pathways or down-stream from classic neurotrans-
mitter systems such as noradrenalin, serotonin or 
dopamine. An alternative possibility is that periph-
eral GLP-1 acts on vagal afferent ﬁ  bers
[89], where 
it could inﬂ  uence GLP-1 neuronal transmission in 
the CNS.
GLP-1R positively regulates neuronal plasticity 
and cell survival as the stimulation of neuron
[51]. 
It was recently reported that GLP-1 and Ex-4 
possess neurotrophic properties and can protect 
neurons against glutamate-induced apoptosis. 
Perry
[87] showed that GLP-1 can reduce the levels 88
Lin
Clinical Medicine: Pathology 2008:1
of Aβ in the brain in vivo and can reduce levels of 
APP in cultured neuronal cells. GLP-1 and Ex-4 
protect cultured hippocampal neurons against death 
induced by Aβ and iron, an oxidative insult. 
Collectively, these data suggests that GLP-1 can 
modify APP processing and protect against oxida-
tive injury. During
[90] showed that intracerebroven-
tricular exendin enhanced associative and spatial 
learning and prevented kainate-induced apoptosis 
of hippocampal neurons in rats. In recent research, 
Perry
[91] showed that GLP-1 (Ex-4) has multiple 
synergistic effects on glucose-dependent insulin 
secretion pathways of pancreatic β-cells and on 
neural plasticity. Their study showed that GLP-1 
(Ex-4) may offer some protection against the sen-
sory peripheral neuropathy induced by pyridoxine. 
Put those data together it seems a potential role for 
these peptides to treat neuropathies.
Parsons
[92] has made a GLP-1 minigene that can 
direct the secretion of active GLP-1 (amino acids 
7–37) to achieve continuous GLP-1 expression to 
lengthen its half-life in vivo. In order to delay half-
life and improve the therapeutic value of GLP-1, 
Youn
[93] chemically modiﬁ  ed GLP-1 with polyeth-
ylene glycol (PEG) and proved that the site-speciﬁ  c 
Lys
34-PEG-GLP-1 was found to have signiﬁ  cantly 
improved in vivo glucose-stabilizing efﬁ  cacy than 
the other PEGylated GLP-1 isomers (His
7- or 
Lys
26-PEG-GLP1). Nevertheless, some of the 
GLP-1-derived agonists with DPP-IV resistance 
appear to be rapidly cleared from the plasma by 
renal clearance. The clinical studies of Ex-4 
showed that daily administration or combination 
therapy with oral anti-diabetic agents was required 
to normalize blood glucose levels. To develop the 
longer-acting molecules that retain the native 
GLP-1 actions is a motivated effort. It is also clear 
that a gene therapy approach exerting long lasting 
effects would have advantages over parenteral 
protein drug delivery. A new gene therapy 
agent: GLP-1/IgG1-Fc fusion construct developed 
by Kuma
[94] showed a unique advantage. Fusing 
active human GLP-1 and mouse IgG1 heavy chain 
constant regions (GLP-1/Fc) Kuma generated a 
plasmid encoding an IgK leader peptide-driven 
secretable fusion protein of the active GLP-1 and 
IgG1-Fc was constructed for mammalian expres-
sion. The researches in vivo and vitro showed that 
the bivalent GLP-1/Fc fusion protein is an effective 
approach for the therapy of T2DM.
In clinic treatment, GLP-1 based therapies for 
T2DM has made progress. Therapy strategies related 
to GLP-1 include injected DPPIV-resistant GLP-1 
mimetics or orally active DPPIV inhibitors
[75,95,96].
The GLP-1 enhancers and DPPIV inhibitors in 
pre-registered by FDA are Vildagliptin (LAF237), 
Sitagliptin (MK-0431); in clinical phase III programs 
are Denagliptin, SYR 322, Saxagliptin (BMS477118); 
in clinical phase II are Ro-0730699, PSN 9301, TA 
6666. GLP-1 mimetic, Byetta-Exenatide, has been 
launched in U.S. (2005). GLP-1 minetics in clinical 
phase III programs is Liraglutide NN2211, in clinical 
phase II programs are ZP-10, BIM-51077, Exenatide-
LAR, and CJC-113
[97].
In summary, with a century of studies, the 
understanding of AD leads us to believe that the 
primary targets in AD are the Aβ and τ protein. 
Commonalities between T2DM and AD and the 
effect of GLP-1 on Aβ encourages us to forecast 
the possibility that GLP-1 is revealed as the 
highlight in further T2DM treatment and will bring 
forth its advantage in the therapy of AD.
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